Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group
M.S. Bruijn
Department of Dermatology, University Medical Centre of Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands
Search for more papers by this authorB. Horváth
Department of Dermatology, University Medical Centre of Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands
Search for more papers by this authorP.C. van Voorst Vader
Department of Dermatology, University Medical Centre of Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands
Search for more papers by this authorR. Willemze
Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands
Search for more papers by this authorM.H. Vermeer
Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands
Search for more papers by this authorM.S. Bruijn
Department of Dermatology, University Medical Centre of Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands
Search for more papers by this authorB. Horváth
Department of Dermatology, University Medical Centre of Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands
Search for more papers by this authorP.C. van Voorst Vader
Department of Dermatology, University Medical Centre of Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands
Search for more papers by this authorR. Willemze
Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands
Search for more papers by this authorM.H. Vermeer
Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands
Search for more papers by this author
References
- 1Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768–85.
- 2Bekkenk MW, Geelen FA, van Voorst Vader PC et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653–61.
- 3Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996; 34: 470–81.
- 4Lange Wantzin G, Thomsen K. Methotrexate in lymphomatoid papulosis. Br J Dermatol 1984; 111: 93–5.
- 5Everett MA. Treatment of lymphomatoid papulosis with methotrexate. Br J Dermatol 1984; 111: 631.
- 6Kempf W, Pfaltz K, Vermeer MH et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118: 4024–35.
- 7Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 1–70.
- 8Lim KS, Foo CC. Disseminated molluscum contagiosum in a patient with chronic plaque psoriasis taking methotrexate. Clin Exp Dermatol 2007; 32: 591–3.
- 9Thomas E, Olive P, Mazyad H et al. Cytomegalovirus-induced pneumonia in a rheumatoid arthritis patient treated with low dose methotrexate. Clin Exp Rheumatol 1997; 15: 583–4.
- 10Tran H, Nourse J, Hall S et al. Immunodeficiency-associated lymphomas. Blood Rev 2008; 22: 261–81.
- 11Rizzi R, Curci P, Delia M et al. Spontaneous remission of ‘methotrexate-associated lymphoproliferative disorders’ after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol 2009; 26: 1–9.
